Great Science
Deep Compassion
Real Impact
Leveraging our long-standing neuroscience
expertise to develop medicines that
make a difference.
Featured News
July 13, 2026
Alkermes’ Alixorexton Demonstrated Sustained Improvement in Wakefulness in Adults With Narcolepsy Type 1 and Type 2 in Long-Term Extension Study Int...
June 17, 2026
Alkermes Presents Detailed Positive Results From Vibrance-2 Phase 2 Study of Alixorexton in Adults With Narcolepsy Type 2 at SLEEP 2026
Science with Purpose
From early discovery to late-stage development, explore the research programs that make up our broad neuroscience portfolio.
Defining the Future of Sleep Medicine
Craig Hopkinson reflects on SLEEP 2026 and how patient-focused language can help inform the future of sleep medicine.
Notable Recognition
We are honored to be recognized as an employer of choice in the life sciences industry. Visit our Awards & Recognition page to see the latest accolades bestowed on Alkermes by leading news and ranking organizations.
R&D Pipeline
We apply our deep neuroscience expertise to develop medicines designed to help people living with complex and difficult-to-treat psychiatric and neurological disorders. We are currently focused on developing these investigational candidates.
- Discovery
- Preclinical
- Phase 1
- Phase 2
- Phase 3
-
Sodium oxybate extended-release oral suspension
-
Idiopathic Hypersomnia
Phase 3
A once-nightly formulation of sodium oxybate for extended-release oral suspension is currently being evaluated for use in adults with idiopathic hypersomnia in a phase 3 study, REVITALYZ. For more information about this study, please visit clinicaltrials.gov/study/NCT06525077.
-
-
Olanzapine and samidorphan
-
Schizophrenia and Bipolar I Disorder (Pediatric)
Phase 3
Olanzapine and samidorphan is currently being evaluated for pediatric use in a phase 3 study, ENLIGHTEN-Youth. For more information about this study, please visit enlightenyouthstudy.com (U.S. audiences only) or clinicaltrials.gov/study/NCT05303064.
-
-
Alixorexton
-
Narcolepsy Type 1
Phase 3
-
Narcolepsy Type 2
Phase 3
-
Idiopathic Hypersomnia
Phase 2
Alixorexton (formerly ALKS 2680) is an investigational, oral orexin 2 receptor agonist in development for the treatment of narcolepsy type 1, narcolepsy type 2 and idiopathic hypersomnia.
Alixorexton is currently being evaluated in the phase 3 Brilliance Studies program in adults with narcolepsy type 1 and narcolepsy type 2, and in Vibrance-3, a phase 2 study in adults with idiopathic hypersomnia. Participants who complete one of the Vibrance or Brilliance studies have the option to continue in a long-term, open-label, safety study evaluating the safety of alixorexton for up to two years.
For more information about enrolling studies, please visit brilliancestudies.com,
vibrancestudies.com (for U.S. audiences only), or clinicaltrials.gov for a list of current studies. -
